| 肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展 |
| 投稿时间：2017-05-31 修订日期：2017-06-20 点此下载全文 |
| 引用本文：王洁,卞莹莹,张川,开国银,陆一鸣.肿瘤坏死因子及其受体在类风湿性关节炎中的研究进展[J].药学实践杂志,2017,35(4):289~293 |
| 摘要点击次数: 1414 |
| 全文下载次数: 1231 |
|
| 基金项目:国家自然科学基金资助项目（30500093，81274162）；国家科技部"重大新药创制"专项（2009ZX09103-690）；上海市科委生物医药领域科技支撑项目（16431904400）；上海市教委科研创新项目（14ZZ077） |
|
| 中文摘要:肿瘤坏死因子α（TNF-α）信号通路是治疗自身免疫性疾病的重要靶点。TNF-α能够结合到2个不同的受体上，通过与受体的结合发挥抗炎、抗风湿的作用。抗TNF-α的药物被广泛应用于类风湿性关节炎（RA）的治疗，如英夫利昔单抗、阿达木单抗等。其在抑制炎症引起的损伤及受损组织的恢复等方面具有重要作用，但是也会引起一定的副作用，如增加感染和恶性肿瘤的风险、引起新的自身免疫性疾病等。这些副作用可能是由于封闭了TNF-α的有益信号引起的，而选择性拮抗肿瘤坏死因子受体（tumor necrosis factor receptor，TNFR）可能是解决TNF-α抗体副作用的一个重要途径，特异性地作用于TNFR的药物具有更加广阔的实用性和安全性。针对TNF-α及其受体的药物在RA中的研究进展进行综述。 |
| 中文关键词:肿瘤坏死因子α 肿瘤坏死因子受体 类风湿性关节炎 药物治疗 |
| |
| Research progress of TNF-α and its receptors in rheumatoid arthritis |
|
|
| Abstract:The TNF-α signaling pathway is a valuable target in the therapy of autoimmune diseases. TNF-α binds to two different receptors and exerts anti-inflammatory and anti-rheumatic effects. The drugs of anti-TNF-α are widely used in rheumatoid arthritis, such as infliximab, adalimumab etc. These TNF blockers have become invaluable tools to reduce damages induced by inflammation and allow recovery of the affected tissues. Unfortunately, this therapy has some drawbacks, such as increasing the risk of infection, malignancy and the incidence rate of new auto-immune diseases. Some of these effects are caused by the unwanted abrogation of beneficial TNF signaling. Therefore, elective antagonism of TNFR is an important approach to alleviate the side effects of TNF-α antibody. The medications specifically targeting the TNFR might have better applicability and safety. In this article, research progresses of TNF-α and its receptors in the therapy of rheumatoid arthritis were reviewed. |
| keywords:tumor necrosis factor alpha(TNF-α) tumor necrosis factor receptor(TNFR) rheumatoid arthritis(RA) drug therapy |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
